The effectiveness of antithrombotic agents in reducing stroke mortality, stroke related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be initiated within 48 hours of symptom onset in acute ischemic stroke patients to reduce stroke mortality and morbidity as long as no contraindications exist. Anticoagulants at doses to prevent deep vein thrombosis are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA.

Edit

• American Academy of Neurology
• The Official Journal of the American Academy of Neurology
• National Institute of Neurological Disorders and Stroke

Edit

• Harold Adams, Robert Adams, Gregory Del Zoppo and Larry B. Goldstein. Guidelines for the Early Management of Patients With Ischemic Stroke: Guidelines Update A Scientific Statement From the Stroke Council of the American Heart Association/American Stroke Association. Stroke Vol. 36, 2005: 916:923
• Brott TG, Clark WM, Grotta JC, et al. Stroke the first hours. Guidelines for acute treatment. Consensus Statement. National Stoke Association. 2000.
• Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese acute stroke trialand the international stroke trial. On behalf of the CAST and IST collaborative groups, Stroke 2000;31:1240-1249.
• Coull BM, Williams LS, Goldstein LB, et al. Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke. Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association) Stroke. 2002;33:1934 -1942.

Edit